{"id":"W2986633517","doi":"10.1016/s0140-6736(19)32591-7","title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":3211,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute for Health and Care Research; Regeneron Pharmaceuticals; Eisai; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Cetuximab; Pembrolizumab; Medicine; Chemotherapy; Head and neck; Oncology; Open label; Internal medicine; Head and neck squamous-cell carcinoma; Head and neck cancer; Basal cell; Radiation therapy; Randomized controlled trial; Surgery; Cancer; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}